Devising a viable global strategy to combat Cholera
BioSpectrum Asia|BioSpectrum Asia June 2023
Since mid-2021, the world is facing an acute upsurge of the 7th cholera pandemic characterised by the number, size and concurrence of multiple outbreaks, the spread to areas free of cholera for decades and alarming high mortality rates. Based on the current situation and lack of vaccines and other resources, the World Health Organisation (WHO) assesses the risk at the global level as very high.
Devising a viable global strategy to combat Cholera

For reasons not yet fully understood, beginning in 2022 the world experienced an unprecedented surge in cholera outbreaks as characterised by the number, size and concurrence. Cholera is an acute, rapidly dehydrating diarrheal disease transmitted through water or food contaminated with the bacteria Vibrio cholerae O1. It is a disease of poverty, primarily affecting people living in areas without access to safe drinking water and inadequate sanitation.

The global burden of cholera is not fully known because of under-reporting, with some affected countries not reporting cases at all to avoid the stigma. One study estimates 1.3 billion people are at risk for cholera in a total of 69 endemic countries, with 2.86 million cholera cases and an estimated 95,000 deaths annually. Most of the global burden is in sub-Saharan Africa (60 per cent ) and South-East Asia (29 per cent ).

In January 2023, WHO declared cholera to be a grade 3 global emergency, the highest risk level. As of March, there were 24 countries reporting outbreaks, a number expected to increase as most countries are not yet in the high transmission season. The Steering Committee of the Global Task Force on Cholera Control (GTFCC) issued a statement that climate change multiplies the risk of cholera around the world, and the upsurge beginning in 2022 may be the new normal.

Unfortunately, the current global supply of vaccines is insufficient to meet the ongoing surge in outbreaks. As a result of the strained global cholera vaccine supply, in late 2022, the WHO International Coordinating Group (ICG), the body which manages emergency supplies of vaccines, temporarily suspended the standard two-dose vaccination schedule in cholera outbreaks and recommended a single dose instead. This strategy, while expanding the coverage of vaccines to a larger population, may be associated with reduced protection in young children.

Bu hikaye BioSpectrum Asia dergisinin BioSpectrum Asia June 2023 sayısından alınmıştır.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.

Bu hikaye BioSpectrum Asia dergisinin BioSpectrum Asia June 2023 sayısından alınmıştır.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.

BIOSPECTRUM ASIA DERGISINDEN DAHA FAZLA HIKAYETümünü görüntüle
Australia invests $1.89B for health and medical research transformation
BioSpectrum Asia

Australia invests $1.89B for health and medical research transformation

The government is investing in a once in a generation transformation of health and medical research in Australia.

time-read
1 min  |
June 2024
NZ suggests new way to prevent rheumatic heart disease progression
BioSpectrum Asia

NZ suggests new way to prevent rheumatic heart disease progression

A new way of delivering treatment to prevent rheumatic heart disease progression is significantly less painful than an almost 70-year-old existing treatment, a University of Otago-led study in New Zealand (NZ) has found.

time-read
1 min  |
June 2024
WHO prequalifies Takeda's dengue vaccine
BioSpectrum Asia

WHO prequalifies Takeda's dengue vaccine

A new vaccine for dengue has received prequalification from the World Health Organization (WHO).

time-read
1 min  |
June 2024
GIBF invests $10M in Israel's Nectin Therapeutics to advance ADCs
BioSpectrum Asia

GIBF invests $10M in Israel's Nectin Therapeutics to advance ADCs

Guangzhou-Israel Biotechnology Fund (GIBF) has invested $10 million in Nectin Therapeutics.

time-read
1 min  |
June 2024
HOYA Group to distribute AIassisted lesion detection device in US
BioSpectrum Asia

HOYA Group to distribute AIassisted lesion detection device in US

Japan-based HOYA Group Company, PENTAX of America, Inc. (PENTAX Medical, a division of HOYA Group) and MAGENTIQ-EYE, an artificial intelligence (AI)-based medical device company, have announced their intention to form a partnership in the field of AI in gastroenterology and to examine further collaboration and strategic partnerships.

time-read
1 min  |
June 2024
Saudi Arabia pledges $500M to protect children from polio
BioSpectrum Asia

Saudi Arabia pledges $500M to protect children from polio

At the first-ever World Economic Forum (WEF) Special Meeting hosted in Riyadh recently, the Kingdom of Saudi Arabia has pledged $500 million over the next five years to support the work of the Global Polio Eradication Initiative (GPEI).

time-read
1 min  |
June 2024
Scientists explore use of COVID-19 variant vaccine against other coronaviruses
BioSpectrum Asia

Scientists explore use of COVID-19 variant vaccine against other coronaviruses

An international consortium of researchers developing a vaccine against troublesome COVID-19 variants will receive additional CEPI funding to investigate whether it could also protect against other deadly coronaviruses.

time-read
1 min  |
June 2024
How Thai Biotech is Thriving with Innovations
BioSpectrum Asia

How Thai Biotech is Thriving with Innovations

Thailand's biotech industry is rapidly evolving, positioning itself as a key player in the ASEAN regions and the global biotechnology landscape. With a strategic focus on research and development, supportive government policies and a burgeoning ecosystem of startups and research institutions, Thailand is emerging as a hotspot for biotech innovation in Southeast Asia.

time-read
2 dak  |
June 2024
Why multi-use real estate is in demand for life sciences companies
BioSpectrum Asia

Why multi-use real estate is in demand for life sciences companies

India's Biocon, Enzene Biosciences, and Meteoric Biopharmacueticals, Japan's Daiichi Sankyo, and Singapore's Hummingbird Bioscience, have all recently sought to lease, acquire, and set up shop in a mixed-use space in the US. And for those companies who wish to enter or expand in the US market, New Jersey is a top choice due to its existing infrastructure, cultural connections, robust talent and location.

time-read
4 dak  |
June 2024
"The dialogue surrounding pharmaceutical gowning is experiencing significant transformation in 2024 & beyond"
BioSpectrum Asia

"The dialogue surrounding pharmaceutical gowning is experiencing significant transformation in 2024 & beyond"

Finland-based Lindström, a leading global provider of workwear, cleanroom workwear, and mat services, is making significant strides in its expansion efforts, particularly in key markets such as India, China, Vietnam, and Turkey.

time-read
5 dak  |
June 2024